WO2016100347A2 - Small molecule inhibitors of egfr and pi3k - Google Patents
Small molecule inhibitors of egfr and pi3k Download PDFInfo
- Publication number
- WO2016100347A2 WO2016100347A2 PCT/US2015/065827 US2015065827W WO2016100347A2 WO 2016100347 A2 WO2016100347 A2 WO 2016100347A2 US 2015065827 W US2015065827 W US 2015065827W WO 2016100347 A2 WO2016100347 A2 WO 2016100347A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mmol
- mol
- quinazolin
- compound
- reaction mixture
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Definitions
- This invention is in the field of medicinal chemistry.
- the invention relates to a new class of small-molecules having a quinazoline structure or a quinoline structure which function as dual inhibitors of EGFR proteins and PI3K proteins, and their use as therapeutics for the treatment of cancer and other diseases.
- Colorectal cancer is the third most prevalent malignancy in the United States with approximately 145,000 new diagnoses and 56,000 deaths estimated for 2005 (see, e.g., Cancer Facts and Figures 2005, Surveillance Research (Washington, D.C. : American Cancer Society, Inc.), 2005). Surgery is the mainstay of treatment for colorectal cancer but recurrence is frequent. Colorectal cancer has proven resistant to chemotherapy, although limited success has been achieved using a combination of 5-fluorouracil and levamisole. Surgery has had the largest impact on survival and, in some patients with limited disease, achieves a cure. However, surgery removes bulk tumor, leaving behind microscopic residual disease which ultimately results in recurrence.
- PI3K is negatively regulated by phosphatase and tensin homolog (PTEN) (see, e.g., Hamada K, et al, 2005 Genes Dev 19 (17): 2054-65). Numerous studies have shown a link between PIK3CA mutation/PTEN loss and EGFR targeted resistance leading to poor overall survival (see, e.g., Atreya CE, Sangale Z, Xu N, et al. Cancer Med. 2013;2: 496-506; Sawai H, et al., BMC Gastroenterol. 2008;8: 56; Bethune G, et al, J Thorac Dis.
- PTEN tensin homolog
- the present invention relates to a new class of small-molecules having a quinazoline structure or quinoline structure which function as dual inhibitors of EGFR protein and PI3K protein, and their use as therapeutics for the treatment of conditions characterized by aberrant EGFR and PI3K expression (e.g., cancer and other diseases (e.g., autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, sperm motility, transplantation rejection, graft rejection, lung injuries, etc)).
- cancer and other diseases e.g., autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, sperm motility, transplantation rejection, graft rejection, lung injuries, etc.
- the compounds of the present invention are useful in treating subjects with EGFR positive colorectal cancer that harbor an activating mutation in PI3K
- the present invention contemplates that exposure of animals (e.g., humans) suffering from a condition characterized by aberrant EGFR protein activity (e.g., ERBBl) and PI3K protein activity (e.g., PBKoc) (e.g., cancer (e.g., and/or cancer related disorders)) to therapeutically effective amounts of drug(s) having a quinazoline structure (e.g., small molecules having a quinazoline structure) or a quinoline structures (e.g., small molecules having a quinoline structure) that inhibit the activity of both EGFR and PI3K will inhibit the growth of cells characterized by aberrant EGFR and PI3K protein expression (e.g., colorectal cancer cells having aberrant EGFR and PI3K protein expression) and/or render such cells as a population more susceptible to the cell death-inducing activity of additional therapeutic drugs (e.g., cancer therapeutic drugs or radiation therapies).
- additional therapeutic drugs e.g., cancer therapeutic
- EGFR and PI3K activity e.g., cancer
- additional agent(s) such as other cell death-inducing or cell cycle disrupting therapeutic drugs (e.g., cancer therapeutic drugs or radiation therapies) (combination therapies), so as to render a greater proportion of the cells (e.g., cancer cells) or supportive cells susceptible to executing the apoptosis program compared to the corresponding proportion of cells in an animal treated only with the therapeutic drug or radiation therapy alone.
- the condition being treated is cancer characterized with aberrant EGFR protein activity (e.g., ERBBl) and PI3K protein activity (e.g., PBKoc) (e.g., colorectal cancer)
- EGFR protein activity e.g., ERBBl
- PI3K protein activity e.g., PBKoc
- combination treatment of animals with a therapeutically effective amount of a compound of the present invention and a course of an anticancer agent produces a greater tumor response and clinical benefit in such animals compared to those treated with the compound or anticancer drugs/radiation alone. Since the doses for all approved anticancer drugs and radiation treatments are known, the present invention contemplates the various combinations of them with the present compounds.
- quinazoline compounds and quinoline compounds function as inhibitors of both EGFR and PI3K, and serve as therapeutics for the treatment of cancer and other diseases.
- the present invention relates to quinazoline compounds and quinoline compounds useful for inhibiting EGFR and PI3K activity (e.g., thereby facilitating cell apoptosis), and increasing the sensitivity of cells to inducers of apoptosis and/or cell cycle arrest.
- Certain quinazoline compounds and quinoline compounds of the present invention may exist as stereoisomers including optical isomers.
- the invention includes all stereoisomers, both as pure individual stereoisomer preparations and enriched preparations of each, and both the racemic mixtures of such stereoisomers as well as the individual diastereomers and enantiomers that may be separated according to methods that are well known to those of skill in the art.
- quinazoline compounds having Formula I having Formula I
- Formulas I and II are not limited to a particular chemical moiety for Rl and R2.
- the particular chemical moiety for Rl and R2 independently include any chemical moiety that permits the resulting compound to inhibit an EGFR protein (e.g., ERBBl) and inhibit a PI3K protein (e.g., POKa).
- an EGFR protein e.g., ERBBl
- a PI3K protein e.g., POKa
- Rl is a substituted or non-substituted aryl moiety.
- Rl is selected from
- the invention further provides processes for preparing any of the compounds of the present invention.
- the invention also provides the use of compounds to induce cell cycle arrest and/or apoptosis in cells characterized with aberrant EGFR protein activity (e.g., ERBB1) and PI3K protein activity (e.g., POKa).
- the invention also relates to the use of compounds for sensitizing cells to additional agent(s), such as inducers of apoptosis and/or cell cycle arrest, and chemoprotection of normal cells through the induction of cell cycle arrest prior to treatment with chemotherapeutic agents.
- the compounds of the invention are useful for the treatment, amelioration, or prevention of disorders, such as those responsive to induction of apoptotic cell death, e.g., disorders characterized by dysregulation of apoptosis, including hyperproliferative diseases such as cancer characterized with cells aberrant EGFR protein activity (e.g., ERBB1) and PI3K protein activity (e.g., PBKa) (e.g., colorectal cancer).
- the compounds can be used to treat, ameliorate, or prevent such types of cancer (e.g., colorectal cancer) that is characterized by resistance to cancer therapies (e.g., those cancer cells which are chemoresistant, radiation resistant, hormone resistant, and the like).
- the cancer is colorectal cancer, head & neck cancer, glioblastoma multiform, and/or non-small cell lung cancer
- the compounds can be used to treat other characterized by aberrant expression of EGFR and PI3K proteins (e.g., autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, sperm motility, transplantation rejection, graft rejection, lung injuries, etc).
- autoimmune disorders e.g., inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, sperm motility, transplantation rejection, graft rejection, lung injuries, etc.
- the invention also provides pharmaceutical compositions comprising the compounds of the invention in a pharmaceutically acceptable carrier.
- the invention also provides kits comprising a compound of the invention and instructions for administering the compound to an animal.
- the kits may optionally contain other therapeutic agents, e.g., anticancer agents or apoptosis-modulating agents.
- the present invention provides methods for simultaneously inhibiting both EGFR protein activity and PI3K protein activity in cells through exposing such cells to one or more of the quinazoline or quinoline compounds of the present invention.
- FIG. 1A-C shows EGFR inhibiting agents.
- FIG. 2A-E shows PI3K inhibiting agents.
- FIG. 3 shows the X-ray Crystal quinolone binding mode in EGFR (ATP competitive site of protein kinases) for Lapatinib (PDB Code: 1XKK) and HKI-272 (PDB Code: 3W2Q).
- FIG. 4A shows the X-ray crystal binding mode of GSK2126458 (PDB Code:3L08) with EGFR and PI3K, the X-ray crystal binding mode of PF-04979064 (PDB Code:4HVB) with PI3K, and the X-ray crystal binding mode of Lapatinib with EGFR.
- FIG. 4B shows the binding mode of BEZ235 in PI3K.
- FIG. 4C shows a comparison of lipid versus protein kinase binding mode of quinoline for Lapatinib and GSK2126458 (PDB Code:3L08).
- FIG. 5 A shows that phosphorylation of EGFR was found to be completely suppressed in HCT-116 tumors (100 mg/kg) at two hours post-dosing of a single oral dose of MOL-162.
- FIG. 5B shows a measurement of cell proliferation for MOL-160, MOL-161, MOL-162, and MOL-163.
- FIG. 5C shows HCT-116 cell viability for various compounds.
- FIG. 5D shows the effect of MOL-162 on pAKT and pEGFR in HCT-116 cells treated for two hours.
- FIG. 6 shows IC50s of various compounds against EGFR and PIK3CA.
- FIG. 7 shows %Growth of select compounds against NCI-60 Compare panel for compounds at 10 ⁇ .
- FIG. 8A, 8B, 8C, 8D, and 8E shows in vivo efficacy of MOL-201 against, HCT-116, A431, COL-205, SK-MEL5 and MDA-MB-468 xenografts.
- anticancer agent refers to any therapeutic agents (e.g., chemotherapeutic compounds and/or molecular therapeutic compounds), antisense therapies, radiation therapies, or surgical interventions, used in the treatment of hyperproliferative diseases such as cancer (e.g., in mammals, e.g.., in humans).
- therapeutic agents e.g., chemotherapeutic compounds and/or molecular therapeutic compounds
- antisense therapies e.g., radiation therapies, or surgical interventions, used in the treatment of hyperproliferative diseases such as cancer (e.g., in mammals, e.g.., in humans).
- prodrug refers to a pharmacologically inactive derivative of a parent "drug” molecule that requires biotransformation (e.g., either spontaneous or enzymatic) within the target physiological system to release, or to convert (e.g. , enzymatically,
- Prodrugs are designed to overcome problems associated with stability, water solubility, toxicity, lack of specificity, or limited bioavailability.
- Exemplary prodrugs comprise an active drug molecule itself and a chemical masking group (e.g., a group that reversibly suppresses the activity of the drug).
- Some prodrugs are variations or derivatives of compounds that have groups cleavable under metabolic conditions. Prodrugs can be readily prepared from the parent compounds using methods known in the art, such as those described in A Textbook of Drug Design and
- prodrugs become pharmaceutically active in vivo or in vitro when they undergo solvolysis under physiological conditions or undergo enzymatic degradation or other biochemical transformation (e.g. , phosphorylation, hydrogenation, dehydrogenation, glycosylation).
- Prodrugs often offer advantages of water solubility, tissue compatibility, or delayed release in the mammalian organism. (See e.g. , Bundgard, Design of Prodrugs, pp. 7-9, 21-24, Elsevier, Amsterdam (1985); and Silverman, The Organic Chemistry of Drug Design and Drug Action, pp. 352-401, Academic Press, San Diego, CA (1992)).
- Common prodrugs include acid derivatives such as esters prepared by reaction of parent acids with a suitable alcohol (e.g.
- salt refers to any salt (e.g. , obtained by reaction with an acid or a base) of a compound of the present invention that is physiologically tolerated in the target animal (e.g., a mammal). Salts of the compounds of the present invention may be derived from inorganic or organic acids and bases.
- acids include, but are not limited to, hydrochloric, hydrobromic, sulfuric, nitric, perchloric, fumaric, maleic, phosphoric, gly colic, lactic, salicylic, succinic, toluene-p-sulfonic, tartaric, acetic, citric, methanesulfonic, ethanesulfonic, formic, benzoic, malonic, sulfonic, naphthalene-2-sulfonic, benzenesulfonic acid, and the like.
- Other acids such as oxalic, while not in themselves pharmaceutically acceptable, may be employed in the preparation of salts useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable acid addition salts.
- bases include, but are not limited to, alkali metal (e.g., sodium) hydroxides, alkaline earth metal (e.g. , magnesium) hydroxides, ammonia, and compounds of formula NW 4 + , wherein W is CM alkyl, and the like.
- alkali metal e.g., sodium
- alkaline earth metal e.g. , magnesium
- W is CM alkyl
- salts include, but are not limited to: acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, flucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, chloride, bromide, iodide,
- salts include anions of the compounds of the present invention compounded with a suitable cation such as Na + , NH 4 + , and NW ⁇ 4 + (wherein W is a C alkyl group), and the like.
- a suitable cation such as Na + , NH 4 + , and NW ⁇ 4 + (wherein W is a C alkyl group), and the like.
- salts of the compounds of the present invention are contemplated as being pharmaceutically acceptable.
- salts of acids and bases that are non-pharmaceutically acceptable may also find use, for example, in the preparation or purification of a
- solvate refers to the physical association of a compound of the invention with one or more solvent molecules, whether organic or inorganic. This physical association often includes hydrogen bonding. In certain instances, the solvate is capable of isolation, for example, when one or more solvate molecules are incorporated in the crystal lattice of the crystalline solid. "Solvate” encompasses both solution-phase and isolable solvates.
- Exemplary solvates include hydrates, ethanolates, and methanolates.
- a therapeutically effective amount refers to that amount of the therapeutic agent sufficient to result in amelioration of one or more symptoms of a disorder, or prevent advancement of a disorder, or cause regression of the disorder.
- a therapeutically effective amount will refer to the amount of a therapeutic agent that decreases the rate of tumor growth, decreases tumor mass, decreases the number of metastases, increases time to tumor progression, or increases survival time by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 100%.
- sensitize and “sensitizing,” as used herein, refer to making, through the administration of a first agent (e.g. , a quinazoline compound of the invention), an animal or a cell within an animal more susceptible, or more responsive, to the biological effects (e.g., promotion or retardation of an aspect of cellular function including, but not limited to, cell division, cell growth, proliferation, invasion, angiogenesis, necrosis, or apoptosis) of a second agent.
- a first agent e.g. , a quinazoline compound of the invention
- biological effects e.g., promotion or retardation of an aspect of cellular function including, but not limited to, cell division, cell growth, proliferation, invasion, angiogenesis, necrosis, or apoptosis
- the sensitizing effect of a first agent on a target cell can be measured as the difference in the intended biological effect (e.g., promotion or retardation of an aspect of cellular function including, but not limited to, cell growth, proliferation, invasion, angiogenesis, or apoptosis) observed upon the administration of a second agent with and without administration of the first agent.
- the intended biological effect e.g., promotion or retardation of an aspect of cellular function including, but not limited to, cell growth, proliferation, invasion, angiogenesis, or apoptosis
- the response of the sensitized cell can be increased by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100%, at least about 150%, at least about 200%, at least about 250%, at least 300%, at least about 350%, at least about 400%, at least about 450%, or at least about 500% over the response in the absence of the first agent.
- Dysregulation of apoptosis refers to any aberration in the ability of (e.g. , predisposition) a cell to undergo cell death via apoptosis.
- Dysregulation of apoptosis is associated with or induced by a variety of conditions, non-limiting examples of which include, autoimmune disorders (e.g. , systemic lupus erythematosus, rheumatoid arthritis, graft-versus-host disease, myasthenia gravis, or Sjogren's syndrome), chronic inflammatory conditions (e.g. , psoriasis, asthma or Crohn's disease), hyperproliferative disorders (e.g. , tumors, B cell lymphomas, or T cell lymphomas), viral infections (e.g. , herpes, papilloma, or HIV), and other conditions such as osteoarthritis and atherosclerosis.
- autoimmune disorders e.g. , systemic lupus erythe
- hyperproliferative disease refers to any condition in which a localized population of proliferating cells in an animal is not governed by the usual limitations of normal growth.
- hyperproliferative disorders include tumors, neoplasms, lymphomas and the like.
- a neoplasm is said to be benign if it does not undergo invasion or metastasis and malignant if it does either of these.
- a "metastatic" cell means that the cell can invade and destroy neighboring body structures.
- Hyperplasia is a form of cell proliferation involving an increase in cell number in a tissue or organ without significant alteration in structure or function.
- Metaplasia is a form of controlled cell growth in which one type of fully differentiated cell substitutes for another type of differentiated cell.
- autoimmune disorder refers to any condition in which an organism produces antibodies or immune cells which recognize the organism's own molecules, cells or tissues.
- Non-limiting examples of autoimmune disorders include autoimmune hemolytic anemia, autoimmune hepatitis, Berger's disease or IgA nephropathy, celiac sprue, chronic fatigue syndrome, Crohn's disease, dermatomyositis, fibromyalgia, graft versus host disease, Grave's disease, Hashimoto's thyroiditis, idiopathic thrombocytopenia purpura, lichen planus, multiple sclerosis, myasthenia gravis, psoriasis, rheumatic fever, rheumatic arthritis, scleroderma, Sjogren's syndrome, systemic lupus erythematosus, type 1 diabetes, ulcerative colitis, vitiligo, and the like.
- neoplastic disease refers to any abnormal growth of cells being either benign (non-cancerous) or malignant (cancerous).
- normal cell refers to a cell that is not undergoing abnormal growth or division. Normal cells are non-cancerous and are not part of any hyperproliferative disease or disorder.
- anti-neoplastic agent refers to any compound that retards the proliferation, growth, or spread of a targeted (e.g. , malignant) neoplasm.
- prevent refers to a decrease in the occurrence of pathological cells (e.g. , hyperproliferative or neoplastic cells) in an animal.
- the prevention may be complete, e.g. , the total absence of pathological cells in a subject.
- the prevention may also be partial, such that the occurrence of pathological cells in a subject is less than that which would have occurred without the present invention.
- pharmaceutically acceptable carrier or “pharmaceutically acceptable vehicle” encompasses any of the standard pharmaceutical carriers, solvents, surfactants, or vehicles. Suitable pharmaceutically acceptable vehicles include aqueous vehicles and nonaqueous vehicles. Standard pharmaceutical carriers and their formulations are described in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA, 19th ed. 1995.
- Buck et al demonstrated that the mTOR inhibitor rapamycin synergizes with the EGFR inhibitor erlotinib in several cell lines that were resistant to erlotinib treatment alone (e.g., Ratushny V, et al., Cell Signal. 2009;21 : 1255-1268). However, the full potential of this synergistic combination was not achieved because rapamycin induces phosphorylation of AKT resulting in pathway reactivation (e.g., Ratushny V, et al., Cell Signal. 2009;21 : 1255-1268).
- the quinazoline and quinoline compounds of the present invention were accordingly synthesized to target the "active cores" for PI3K and the "active cores” for EGFR, thereby rendering such compounds as having "dual potency" against EGFR protein activity (e.g., ERBBl) and PI3K protein activity (e.g., PBKoc).
- EGFR protein activity e.g., ERBBl
- PI3K protein activity e.g., PBKoc
- the present invention relates to compounds which function as inhibitors of EGFR protein activity (e.g., ERBBl) and PI3K protein activity (e.g., PBKoc).
- EGFR protein activity e.g., ERBBl
- PI3K protein activity e.g., PBKoc
- these compounds sensitize cells to inducers of apoptosis and/or cell cycle arrest and, in some instances, themselves induce apoptosis and/or cell cycle arrest.
- the invention relates to methods of sensitizing cells to inducers of apoptosis and/or cell cycle arrest and to methods of inducing apoptosis and/or cell cycle arrest in cells, comprising contacting the cells with a compound of the invention alone or in combination with additional agent(s), e.g. , an inducer of apoptosis or a cell cycle disrupter.
- additional agent(s) e.g. , an inducer of apoptosis or a cell cycle disrupter.
- the invention further relates to methods of treating, ameliorating, or preventing conditions in a patient characterized with cells having aberrant EGFR protein activity (e.g., ERBB1) and PI3K protein activity (e.g., PBKa), such as those conditions that are responsive to induction of apoptosis, comprising administering to the patient a compound of the invention and additional agent(s), e.g. , an inducer of apoptosis.
- EGFR protein activity e.g., ERBB1
- PI3K protein activity e.g., PBKa
- Such disorders include those characterized by a dysregulation of apoptosis and those characterized by the proliferation of cells having aberrant EGFR protein activity (e.g., ERBBl) and PI3K protein activity (e.g., PBKoc) (e.g., colorectal cancer).
- EGFR protein activity e.g., ERBBl
- PI3K protein activity e.g., PBKoc
- the compounds of the present invention are useful in treating subjects with EGFR positive colorectal cancer that harbor an activating mutation in PBKa or are PTEN null.
- quinazoline compounds having Formula I having Formula I
- Formulas I and II are not limited to a particular chemical moiety for Rl and R2.
- the particular chemical moiety for Rl and R2 independently include any chemical moiety that permits the resulting compound to inhibit an EGFR protein (e.g., ERBBl) and inhibit a PI3K protein (e.g., POKa).
- Rl is a substituted or non-substituted aryl moiety.
- An important aspect of the present invention is that compounds of the invention induce cell cycle arrest and/or apoptosis and also potentiate the induction of cell cycle arrest and/or apoptosis either alone or in response to additional apoptosis induction signals. Therefore, it is contemplated that these compounds sensitize cells to induction of cell cycle arrest and/or apoptosis, including cells that are resistant to such inducing stimuli.
- the EGFR and PI3K inhibitors of the present invention e.g., quinazoline compounds
- quinoline compounds can be used to induce apoptosis in any disorder that can be treated, ameliorated, or prevented by the induction of apoptosis.
- compositions and methods of the present invention are used to treat diseased cells, tissues, organs, or pathological conditions and/or disease states in an animal (e.g. , a mammalian patient including, but not limited to, humans and veterinary animals).
- an animal e.g. , a mammalian patient including, but not limited to, humans and veterinary animals.
- various diseases and pathologies are amenable to treatment or prophylaxis using the present methods and compositions.
- a non-limiting exemplary list of these diseases and conditions includes, but is not limited to, colorectal cancer, non-small cell lung carcinoma, head or neck carcinoma, glioblastoma multiform cancer, pancreatic cancer, breast cancer, prostate cancer, lymphoma, skin cancer, colon cancer, melanoma, malignant melanoma, ovarian cancer, brain cancer, primary brain carcinoma, head-neck cancer, glioma, glioblastoma, liver cancer, bladder cancer, non-small cell lung cancer, , breast carcinoma, ovarian carcinoma, lung carcinoma, small-cell lung carcinoma, Wilms' tumor, cervical carcinoma, testicular carcinoma, bladder carcinoma, pancreatic carcinoma, stomach carcinoma, colon carcinoma, prostatic carcinoma, genitourinary carcinoma, thyroid carcinoma, esophageal carcinoma, myeloma, multiple myeloma, adrenal carcinoma, renal cell carcinoma, endometrial carcinoma, adrenal cortex carcinoma, malignant pancreatic insulinoma, malignant carcinoid carcinoma,
- choriocarcinoma mycosis fungoides, malignant hypercalcemia, cervical hyperplasia, leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, chronic granulocytic leukemia, acute granulocytic leukemia, hairy cell leukemia, neuroblastoma, rhabdomyosarcoma, Kaposi's sarcoma, polycythemia vera, essential thrombocytosis, Hodgkin's disease, non-Hodgkin's lymphoma, soft-tissue sarcoma, osteogenic sarcoma, primary macroglobulinemia, and retinoblastoma, and the like, T and B cell mediated autoimmune diseases; inflammatory diseases; infections; hyperproliferative diseases; AIDS; degenerative conditions, vascular diseases, and the like.
- the cancer cells being treated are meta
- the disorder is any disorder having cells having aberrant EGFR protein activity (e.g., ERBB1) and PI3K protein activity (e.g., POKa) (e.g., autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, sperm motility, transplantation rejection, graft rejection, lung injuries, etc)).
- EGFR protein activity e.g., ERBB1
- PI3K protein activity e.g., POKa
- autoimmune disorders e.g., autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, sperm motility, transplantation rejection, graft rejection, lung injuries, etc
- autoimmune disorders e.g., inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases,
- Some embodiments of the present invention provide methods for administering an effective amount of a compound of the invention and at least one additional therapeutic agent (including, but not limited to, chemotherapeutic antineoplastics, apoptosis-modulating agents, antimicrobials, antivirals, antifungals, and anti-inflammatory agents) and/or therapeutic technique (e.g. , surgical intervention, and/or radiotherapies).
- the additional therapeutic agent(s) is an anticancer agent.
- suitable anticancer agents are contemplated for use in the methods of the present invention. Indeed, the present invention contemplates, but is not limited to,
- anticancer agents such as: agents that induce apoptosis;
- polynucleotides e.g. , anti-sense, ribozymes, siRNA
- polypeptides e.g. , enzymes and antibodies
- biological mimetics alkaloids; alkylating agents; antitumor antibiotics;
- antimetabolites include hormones; platinum compounds; monoclonal or polyclonal antibodies (e.g., antibodies conjugated with anticancer drugs, toxins, defensins), toxins; radionuclides; biological response modifiers (e.g. , interferons (e.g. , IFN-a) and interleukins (e.g. , IL-2)); adoptive immunotherapy agents; hematopoietic growth factors; agents that induce tumor cell
- chemotherapeutic compounds and anticancer therapies suitable for coadministration with the disclosed compounds are known to those skilled in the art.
- anticancer agents comprise agents that induce or stimulate apoptosis.
- Agents that induce apoptosis include, but are not limited to, radiation (e.g. , X-rays, gamma rays, UV); tumor necrosis factor (TNF)-related factors (e.g., TNF family receptor proteins, TNF family ligands, TRAIL, antibodies to TRAIL-Rl or TRAIL-R2); kinase inhibitors (e.g.
- epidermal growth factor receptor (EGFR) kinase inhibitor vascular growth factor receptor (VGFR) kinase inhibitor, fibroblast growth factor receptor (FGFR) kinase inhibitor, platelet- derived growth factor receptor (PDGFR) kinase inhibitor, and Bcr-Abl kinase inhibitors (such as GLEEVEC)); antisense molecules; antibodies (e.g., HERCEPTIN, RITUXAN, ZEVALIN, and AVASTIN); anti-estrogens (e.g., raloxifene and tamoxifen); anti-androgens (e.g., flutamide, bicalutamide, finasteride, aminoglutethamide, ketoconazole, and corticosteroids);
- EGFR epidermal growth factor receptor
- VGFR vascular growth factor receptor
- FGFR fibroblast growth factor receptor
- PDGFR platelet- derived growth factor receptor
- COX-2 cyclooxygenase 2
- COX-2 inhibitors e.g. , celecoxib, meloxicam, NS-398, and non-steroidal anti-inflammatory drugs (NSAIDs)
- anti-inflammatory drugs e.g., butazolidin, DECADRON, DELTASONE, dexamethasone, dexamethasone intensol, DEXONE, HEXADROL,
- PEDIAPRED phenylbutazone, PLAQUENIL, prednisolone, prednisone, PRELONE, and TANDEARIL
- cancer chemotherapeutic drugs e.g., irinotecan (CAMPTOSAR), CPT-11, fludarabine (FLUDARA), dacarbazine (DTIC), dexamethasone, mitoxantrone, MYLOTARG, VP-16, cisplatin, carboplatin, oxaliplatin, 5-FU, doxorubicin, gemcitabine, bortezomib, gefitinib, bevacizumab, TAXOTERE or TAXOL); cellular signaling molecules; ceramides and cytokines; staurosporine, and the like.
- irinotecan CAMPTOSAR
- CPT-11 CPT-11
- fludarabine FLUDARA
- dexamethasone
- compositions and methods of the present invention provide a compound of the invention and at least one anti-hyperproliferative or antineoplastic agent selected from alkylating agents, antimetabolites, and natural products (e.g., herbs and other plant and/or animal derived compounds).
- at least one anti-hyperproliferative or antineoplastic agent selected from alkylating agents, antimetabolites, and natural products (e.g., herbs and other plant and/or animal derived compounds).
- Alkylating agents suitable for use in the present compositions and methods include, but are not limited to: 1) nitrogen mustards (e.g. , mechlorethamine, cyclophosphamide, ifosfamide, melphalan (L-sarcolysin); and chlorambucil); 2) ethylenimines and methylmelamines (e.g. , hexamethylmelamine and thiotepa); 3) alkyl sulfonates (e.g. , busulfan); 4) nitrosoureas (e.g., carmustine (BCNU); lomustine (CCNU); semustine (methyl-CCNU); and streptozocin
- nitrogen mustards e.g. , mechlorethamine, cyclophosphamide, ifosfamide, melphalan (L-sarcolysin); and chlorambucil
- 2) ethylenimines and methylmelamines e
- streptozotocin streptozotocin
- DTIC dacarbazine
- antimetabolites suitable for use in the present compositions and methods include, but are not limited to: 1) folic acid analogs (e.g. , methotrexate (amethopterin)); 2) pyrimidine analogs (e.g., fluorouracil (5-fluorouracil; 5-FU), floxuridine (fluorode-oxyuridine; FudR), and cytarabine (cytosine arabinoside)); and 3) purine analogs (e.g. , mercaptopurine (6- mercaptopurine; 6-MP), thioguanine (6-thioguanine; TG), and pentostatin (2'- deoxycoformycin)).
- folic acid analogs e.g. , methotrexate (amethopterin)
- pyrimidine analogs e.g., fluorouracil (5-fluorouracil; 5-FU), floxuridine (fluorode-oxyuridine; FudR), and c
- chemotherapeutic agents suitable for use in the
- compositions and methods of the present invention include, but are not limited to: 1) vinca alkaloids (e.g., vinblastine (VLB), vincristine); 2) epipodophyllotoxins (e.g., etoposide and teniposide); 3) antibiotics (e.g., dactinomycin (actinomycin D), daunorubicin (daunomycin; rubidomycin), doxorubicin, bleomycin, plicamycin (mithramycin), and mitomycin (mitomycin C)); 4) enzymes (e.g. , L-asparaginase); 5) biological response modifiers (e.g.
- vinca alkaloids e.g., vinblastine (VLB), vincristine
- epipodophyllotoxins e.g., etoposide and teniposide
- antibiotics e.g., dactinomycin (actinomycin D), daunorubicin (d
- interferon-alfa platinum coordinating complexes (e.g., cisplatin (cis-DDP) and carboplatin); 7) anthracenediones (e.g. , mitoxantrone); 8) substituted ureas (e.g. , hydroxyurea); 9) methylhydrazine derivatives (e.g. , procarbazine (N-methylhydrazine; MIH)); 10) adrenocortical suppressants (e.g. , mitotane (o,p'-DDD) and aminoglutethimide); 11) adrenocorticosteroids (e.g.
- progestins e.g. , hydroxy progesterone caproate, medroxyprogesterone acetate, and megestrol acetate
- estrogens e.g., diethylstilbestrol and ethinyl estradiol
- antiestrogens e.g., tamoxifen
- 15) androgens e.g. , testosterone propionate and fiuoxymesterone
- 16 antiandrogens e.g. , flutamide
- gonadotropin-releasing hormone analogs e.g. , leuprolide
- any oncolytic agent that is routinely used in a cancer therapy context finds use in the compositions and methods of the present invention.
- the U.S. Food and Drug Administration maintains a formulary of oncolytic agents approved for use in the United States. International counterpart agencies to the U.S.F.D.A. maintain similar formularies.
- Table 1 provides a list of exemplary antineoplastic agents approved for use in the U.S. Those skilled in the art will appreciate that the "product labels" required on all U.S. approved chemotherapeutics describe approved indications, dosing information, toxicity data, and the like, for the exemplary agents.
- Anticancer agents further include compounds which have been identified to have anticancer activity. Examples include, but are not limited to, 3-AP, 12-O-tetradecanoylphorbol- 13-acetate, 17AAG, 852A, ABI-007, ABR-217620, ABT-751, ADI-PEG 20, AE-941, AG- 013736, AGRO100, alanosine, AMG 706, antibody G250, antineoplastons, AP23573, apaziquone, APC8015, atiprimod, ATN-161, atrasenten, azacitidine, BB-10901, BCX-1777, bevacizumab, BG00001, bicalutamide, BMS 247550, bortezomib, bryostatin-1, buserelin, calcitriol, CCI-779, CDB-2914, cefixime, cetuximab, CG0070, cilengitide, clofarabine, combreta
- anticancer agents and other therapeutic agents those skilled in the art are referred to any number of instructive manuals including, but not limited to, the Physician's Desk Reference and to Goodman and Gilman's "Pharmaceutical Basis of Therapeutics" tenth edition, Eds. Hardman et al , 2002.
- the present invention provides methods for administering a compound of the invention with radiation therapy.
- the invention is not limited by the types, amounts, or delivery and administration systems used to deliver the therapeutic dose of radiation to an animal.
- the animal may receive photon radiotherapy, particle beam radiation therapy, other types of radiotherapies, and combinations thereof.
- the radiation is delivered to the animal using a linear accelerator.
- the radiation is delivered using a gamma knife.
- the source of radiation can be external or internal to the animal.
- External radiation therapy is most common and involves directing a beam of high-energy radiation to a tumor site through the skin using, for instance, a linear accelerator. While the beam of radiation is localized to the tumor site, it is nearly impossible to avoid exposure of normal, healthy tissue. However, external radiation is usually well tolerated by animals.
- Internal radiation therapy involves implanting a radiation-emitting source, such as beads, wires, pellets, capsules, particles, and the like, inside the body at or near the tumor site including the use of delivery systems that specifically target cancer cells (e.g. , using particles attached to cancer cell binding ligands). Such implants can be removed following treatment, or left in the body inactive.
- Types of internal radiation therapy include, but are not limited to, brachy therapy, interstitial irradiation, intracavity irradiation, radioimmunotherapy, and the like.
- the animal may optionally receive radiosensitizers (e.g. , metronidazole, misonidazole, intra-arterial Budr, intravenous iododeoxyuridine (IudR), nitroimidazole, 5-substituted-4- nitroimidazoles, 2H-isoindolediones, [[(2-bromoethyl)-andno]methyl]-nitro-lH-imidazole-l- ethanol, nitroaniline derivatives, DNA-affinic hypoxia selective cytotoxins, halogenated DNA ligand, 1,2,4 benzotriazine oxides, 2-nitroimidazole derivatives, fluorine-containing nitroazole derivatives, benzamide, nicotinamide, acridine-intercalator, 5-thiotretrazole derivative, 3-nitro- 1,2,4-triazole, 4,5-dinitroimidazole derivative, hydroxylated texaphrins
- Radiosensitizers enhance the killing of tumor cells. Radioprotectors protect healthy tissue from the harmful effects of radiation.
- Radiotherapy any type of radiation can be administered to an animal, so long as the dose of radiation is tolerated by the animal without unacceptable negative side-effects.
- Suitable types of radiotherapy include, for example, ionizing (electromagnetic) radiotherapy (e.g. , X-rays or gamma rays) or particle beam radiation therapy (e.g. , high linear energy radiation).
- Ionizing radiation is defined as radiation comprising particles or photons that have sufficient energy to produce ionization, i.e. , gain or loss of electrons (as described in, for example, U.S. 5,770,581 incorporated herein by reference in its entirety).
- the effects of radiation can be at least partially controlled by the clinician.
- the dose of radiation is fractionated for maximal target cell exposure and reduced toxicity.
- the total dose of radiation administered to an animal is about .01 Gray (Gy) to about 100 Gy.
- about 10 Gy to about 65 Gy e.g., about 15 Gy, 20 Gy, 25 Gy, 30 Gy, 35 Gy, 40 Gy, 45 Gy, 50 Gy, 55 Gy, or 60 Gy
- a complete dose of radiation can be administered over the course of one day
- the total dose is ideally fractionated and administered over several days.
- radiotherapy is administered over the course of at least about 3 days, e.g., at least 5, 7, 10, 14, 17, 21, 25, 28, 32, 35, 38, 42, 46, 52, or 56 days (about 1-8 weeks).
- a daily dose of radiation will comprise approximately 1-5 Gy (e.g. , about 1 Gy, 1.5 Gy, 1.8 Gy, 2 Gy, 2.5 Gy, 2.8 Gy, 3 Gy, 3.2 Gy, 3.5 Gy, 3.8 Gy, 4 Gy, 4.2 Gy, or 4.5 Gy), or 1-2 Gy (e.g. , 1.5-2 Gy).
- the daily dose of radiation should be sufficient to induce destruction of the targeted cells.
- radiation is not administered every day, thereby allowing the animal to rest and the effects of the therapy to be realized.
- radiation desirably is administered on 5 consecutive days, and not administered on 2 days, for each week of treatment, thereby allowing 2 days of rest per week.
- radiation can be administered 1 day/week, 2 days/week, 3 days/week, 4 days/week, 5 days/week, 6 days/week, or all 7 days/week, depending on the animal's responsiveness and any potential side effects.
- Radiation therapy can be initiated at any time in the therapeutic period. In one embodiment, radiation is initiated in week 1 or week 2, and is administered for the remaining duration of the therapeutic period. For example, radiation is administered in weeks 1-6 or in weeks 2-6 of a therapeutic period comprising 6 weeks for treating, for instance, a solid tumor. Alternatively, radiation is administered in weeks 1-5 or weeks 2-5 of a therapeutic period comprising 5 weeks.
- These exemplary radiotherapy administration schedules are not intended, however, to limit the present invention.
- Antimicrobial therapeutic agents may also be used as therapeutic agents in the present invention. Any agent that can kill, inhibit, or otherwise attenuate the function of microbial organisms may be used, as well as any agent contemplated to have such activities. Antimicrobial agents include, but are not limited to, natural and synthetic antibiotics, antibodies, inhibitory proteins (e.g. , defensins), antisense nucleic acids, membrane disruptive agents and the like, used alone or in combination. Indeed, any type of antibiotic may be used including, but not limited to, antibacterial agents, antiviral agents, antifungal agents, and the like.
- a compound of the invention and one or more therapeutic agents or anticancer agents are administered to an animal under one or more of the following conditions: at different periodicities, at different durations, at different
- the compound is administered prior to the therapeutic or anticancer agent, e.g. , 0.5, 1, 2, 3, 4, 5, 10, 12, or 18 hours, 1, 2, 3, 4, 5, or 6 days, or 1, 2, 3, or 4 weeks prior to the administration of the therapeutic or anticancer agent.
- the compound is administered after the therapeutic or anticancer agent, e.g. , 0.5, 1, 2, 3, 4, 5, 10, 12, or 18 hours, 1, 2, 3, 4, 5, or 6 days, or 1, 2, 3, or 4 weeks after the administration of the anticancer agent.
- the compound and the therapeutic or anticancer agent are administered concurrently but on different schedules, e.g., the compound is administered daily while the therapeutic or anticancer agent is
- the compound is administered once a week, once every two weeks, once every three weeks, or once every four weeks.
- the compound is administered once a week while the therapeutic or anticancer agent is administered daily, once a week, once every two weeks, once every three weeks, or once every four weeks.
- compositions within the scope of this invention include all compositions wherein the compounds of the present invention are contained in an amount which is effective to achieve its intended purpose. While individual needs vary, determination of optimal ranges of effective amounts of each component is within the skill of the art.
- the compounds may be administered to mammals, e.g. humans, orally at a dose of 0.0025 to 50 mg/kg, or an equivalent amount of the pharmaceutically acceptable salt thereof, per day of the body weight of the mammal being treated for disorders responsive to induction of apoptosis. In one embodiment, about 0.01 to about 25 mg/kg is orally administered to treat, ameliorate, or prevent such disorders.
- the dose is generally about one-half of the oral dose.
- a suitable intramuscular dose would be about 0.0025 to about 25 mg/kg, or from about 0.01 to about 5 mg/kg.
- the unit oral dose may comprise from about 0.01 to about 1000 mg, for example, about 0.1 to about 100 mg of the compound.
- the unit dose may be administered one or more times daily as one or more tablets or capsules each containing from about 0.1 to about 10 mg, conveniently about 0.25 to 50 mg of the compound or its solvates.
- the compound may be present at a concentration of about 0.01 to 100 mg per gram of carrier. In a one embodiment, the compound is present at a concentration of about 0.07-1.0 mg/ml, for example, about 0.1-0.5 mg/ml, and in one embodiment, about 0.4 mg/ml.
- the compounds of the invention may be administered as part of a pharmaceutical preparation containing suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the compounds into preparations which can be used pharmaceutically.
- suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the compounds into preparations which can be used pharmaceutically.
- the preparations particularly those preparations which can be administered orally or topically and which can be used for one type of administration, such as tablets, dragees, slow release lozenges and capsules, mouth rinses and mouth washes, gels, liquid suspensions, hair rinses, hair gels, shampoos and also preparations which can be administered rectally, such as suppositories, as well as suitable solutions for administration by intravenous infusion, injection, topically or orally, contain from about 0.01 to 99 percent, in one embodiment from about 0.25 to 75 percent of active compound(s), together with the excipient.
- compositions of the invention may be administered to any patient which may experience the beneficial effects of the compounds of the invention.
- mammals e.g. , humans, although the invention is not intended to be so limited.
- Other patients include veterinary animals (cows, sheep, pigs, horses, dogs, cats and the like).
- the compounds and pharmaceutical compositions thereof may be administered by any means that achieve their intended purpose.
- administration may be by parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, transdermal, buccal, intrathecal, intracranial, intranasal or topical routes.
- administration may be by the oral route.
- the dosage administered will be dependent upon the age, health, and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired.
- compositions of the present invention are manufactured in a manner which is itself known, for example, by means of conventional mixing, granulating, dragee- making, dissolving, or lyophilizing processes.
- pharmaceutical preparations for oral use can be obtained by combining the active compounds with solid excipients, optionally grinding the resulting mixture and processing the mixture of granules, after adding suitable auxiliaries, if desired or necessary, to obtain tablets or dragee cores.
- Suitable excipients are, in particular, fillers such as saccharides, for example lactose or sucrose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example tricalcium phosphate or calcium hydrogen phosphate, as well as binders such as starch paste, using, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, tragacanth, methyl cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, and/or polyvinyl pyrrolidone.
- fillers such as saccharides, for example lactose or sucrose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example tricalcium phosphate or calcium hydrogen phosphate, as well as binders such as starch paste, using, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, tragacanth, methyl cellulose,
- disintegrating agents may be added such as the above- mentioned starches and also carboxymethyl-starch, cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof, such as sodium alginate.
- Auxiliaries are, above all, flow-regulating agents and lubricants, for example, silica, talc, stearic acid or salts thereof, such as magnesium stearate or calcium stearate, and/or polyethylene glycol.
- Dragee cores are provided with suitable coatings which, if desired, are resistant to gastric juices.
- concentrated saccharide solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, polyethylene glycol and/or titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures.
- suitable cellulose preparations such as acetylcellulose phthalate or hydroxypropylmethylcellulose phthalate, are used.
- Dye stuffs or pigments may be added to the tablets or dragee coatings, for example, for identification or in order to characterize combinations of active compound doses.
- Other pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer such as glycerol or sorbitol.
- the push-fit capsules can contain the active compounds in the form of granules which may be mixed with fillers such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
- the active compounds are in one embodiment dissolved or suspended in suitable liquids, such as fatty oils, or liquid paraffin.
- stabilizers may be added.
- Possible pharmaceutical preparations which can be used rectally include, for example, suppositories, which consist of a combination of one or more of the active compounds with a suppository base.
- Suitable suppository bases are, for example, natural or synthetic triglycerides, or paraffin hydrocarbons.
- gelatin rectal capsules which consist of a combination of the active compounds with a base.
- Possible base materials include, for example, liquid triglycerides, polyethylene glycols, or paraffin hydrocarbons.
- Suitable formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form, for example, water-soluble salts and alkaline solutions.
- suspensions of the active compounds as appropriate oily injection suspensions may be administered.
- Suitable lipophilic solvents or vehicles include fatty oils, for example, sesame oil, or synthetic fatty acid esters, for example, ethyl oleate or triglycerides or polyethylene glycol-400.
- Aqueous injection suspensions may contain substances which increase the viscosity of the suspension include, for example, sodium carboxymethyl cellulose, sorbitol, and/or dextran.
- the suspension may also contain stabilizers.
- the topical compositions of this invention are formulated in one embodiment as oils, creams, lotions, ointments and the like by choice of appropriate carriers.
- Suitable carriers include vegetable or mineral oils, white petrolatum (white soft paraffin), branched chain fats or oils, animal fats and high molecular weight alcohol (greater than C 12 ).
- the carriers may be those in which the active ingredient is soluble.
- Emulsifiers, stabilizers, humectants and antioxidants may also be included as well as agents imparting color or fragrance, if desired.
- transdermal penetration enhancers can be employed in these topical formulations. Examples of such enhancers can be found in U.S. Pat. Nos. 3,989,816 and 4,444,762; each herein
- Ointments may be formulated by mixing a solution of the active ingredient in a vegetable oil such as almond oil with warm soft paraffin and allowing the mixture to cool.
- a vegetable oil such as almond oil
- a typical example of such an ointment is one which includes about 30% almond oil and about 70% white soft paraffin by weight.
- Lotions may be conveniently prepared by dissolving the active ingredient, in a suitable high molecular weight alcohol such as propylene glycol or polyethylene glycol.
- active cores for each target were separately generated and such cores compared with high activity against both kinases. Such cores were cross-checked for selectivity. Three 'selective' cores were identified. X-ray crystal structures of the active and selective cores were analyzed for binding modes.
- Fig. 3 shows the X-ray Crystal quinolone binding mode in EGFR (ATP competitive site of protein kinases) for Lapatinib (PDB Code: 1XKK) and HKI-272 (PDB Code: 3W2Q).
- Lapatinib the quinoline nitrogen forms hydrogen bond with hinge backbone MET793.
- the 6 position of quinazoline ring system is out towards solvent which is flipped relative to the PI3K binding mode of quinoline.
- HKI-272 quinoline with 3-nitrile
- a similar binding mode as the quinazoline core is maintained, but flipped when compared to PI3K binding mode. SAR between the two series is anticipated to be convergent.
- Fig. 4A shows the X-ray crystal binding mode of GSK2126458 (PDB Code:3L08) with
- Fig. 4B shows the binding mode of BEZ235 in PI3K.
- the model of BEZ235 binding in PI3K quinoline nitrogen forms hydrogen bond with hinge backbone valine.
- the second quinoline off the 6 position sits within the PI3K specificity pocket.
- the nitrile interacts with LYS833 and aromatic groups is bridge between ribose binding pocket and phosophate binging pocket.
- Fig. 4C shows a comparison of lipid versus protein kinase binding mode of quinoline for Lapatinib and GSK2126458 (PDB Code:3L08). As shown, the binding mode of quinoline (quinazoline) core is flipped in PI3K versus EGFR.
- e selected and ligands were designed for potency against EGFR and PIK3CA.
- the respective core portions of the molecules display structural motifs of common core structures that have activity against PIK3CA or EGFR. These common cores served as the basis for designing new molecules with potential activity against both EGFR and PI3K.
- Such cores were utilized with known binding modes of molecules in their respective active sites of EGFR and PI3K resulting in the designing of novel ligands with activity against both (see, Fig. 4C).
- MOL-162 which is significantly more soluble than MOL-153, emerged from these efforts.
- phosphorylation of EGFR was found to be completely suppressed in HCT-116 tumors (100 mg/kg) at two hours post-dosing of a single oral dose of MOL-162.
- Phosphorylation of AKT was not as strongly inhibited.
- additional synthesis of MOL-162 is needed to allow a full
- Fig. 5B shows a measurement of cell proliferation for MOL-160, MOL-161, MOL-162, and MOL-163.
- Cell proliferation was determined using the Cell Titer Glo assay (Promega, Madison, WI). Cell lines were seeded at a density between 2,000 and 5,000 cells per well in a 96-well plate. Twenty four hours after plating, cells were dosed with varying concentrations of drug, either as a single agent or in combination. The signal for Cell Titer Glo was determined 72 or 96 hours after dosing.
- Fig. 5C shows HCT-116 cell viability for various compounds.
- Fig. 5D shows the effect of MOL-162 on pAKT and pEGFR in HCT-116 cells treated for two hours.
- Fig. 6 shows IC50s of various compounds against EGFR and PIK3CA.
- Various compounds were tested for their ability to inhibit EGFR and PIK3CA.
- the assays determining inhibitions are given in Example 2 Assays - Z ' -LYTE® and ADAPTA.
- Fig. 7 shows %Growth of select compounds against NCI-60 Compare panel for compounds at 10 ⁇ .
- Dual EGFR and PIK3CA inhibitors suppressed tumor growth of NCI-60 cell panel in vitro.
- MOL-201 demonstrated broad cell kill (negative growth at 10 uM) within the panel. The method is outlined in Example 2 - NCI COMPARE Panel.
- Fig. 8A, 8B, 8C, 8D, and 8E show in vivo efficacy of MOL-201 against, HCT-116, A431, COL-205, SK-MEL5 and MDA-MB-468 xenografts.
- MOL-201 was well tolerated by mice with no clinical observations of toxicity treated daily for 10 days at 20 and 100 mg/kg. Anti-tumor activity observed at higher dose in HCT-116, A431, SK-MEL5 and COL-205 xenografts as indicated by T/C and T-C values. MOL-201 elicited anti-tumor activity at lower dose of 20 mg/kg. The method is outlined in Example 2 - Xenograft Studies. Example 2.
- Example 1 The materials and methods for Example 1 are described.
- the Z ' -LYTE® biochemical assay employs a fluorescence-based, coupled- enzyme format and is based on the differential sensitivity of phosphorylated and non- phosphorylated peptides to proteolytic cleavage (Fig. 6).
- the peptide substrate is labeled with two fluorophores— one at each end— that make up a FRET pair.
- the kinase transfers the gamma-phosphate of ATP to a single tyrosine, serine or threonine residue in a synthetic FRET-peptide.
- a site-specific protease recognizes and cleaves non-phosphorylated FRET-peptides.
- FRET-peptides suppresses cleavage by the Development Reagent. Cleavage disrupts FRET between the donor (i.e., coumarin) and acceptor (i.e., fluorescein) fluorophores on the FRET-peptide, whereas uncleaved, phosphorylated FRET-peptides maintain FRET.
- a ratiometric method which calculates the ratio (the Emission Ratio) of donor emission to acceptor emission after excitation of the donor fluorophore at 400 nm, is used to quantitate reaction progress. A significant benefit of this ratiometric method for quantitating reaction progress is the elimination of well-to-well variations in FRET-peptide concentration and signal intensities. As a result, the assay yields very high Z ' -factor values (>0.7) at a low percent phosphorylation.
- Both cleaved and uncleaved FRET-peptides contribute to the fluorescence signals and therefore to the Emission Ratio.
- the extent of phosphorylation of the FRET-peptide can be calculated from the Emission Ratio.
- the Emission Ratio will remain low if the FRET-peptide is phosphorylated (i.e., no kinase inhibition) and will be high if the FRET-peptide is non- phosphorylated (i.e., kinase inhibition).
- the ADAPTA universal kinase assay is a homogenous, fluorescent based immunoassay for the detection of ADP. In contrast to ATP depletion assays, the ADAPTA assay is extremely sensitive to ADP formation such that a majority of the signal change occurs in the first 10-20% conversion of ATP to ADP. This makes the ADAPTA universal kinase assay ideally suited for use with low activity kinases.
- the principle of the ADAPTA universal kinase assay is outlined below.
- the assay itself can be divided into two phases: a kinase reaction phase, and an ADP detection phase.
- a kinase reaction phase all components required for the kinase reaction are added to the well, and the reaction is allowed to incubate for 60 minutes.
- a detection solution consisting of a europium labeled anti-ADP antibody, an Alexa Fluor® 647 labeled ADP tracer, and EDTA (to stop the kinase reaction) is added to the assay well.
- ADP formed by the kinase reaction (in the absence of an inhibitor) will displace the Alexa Fluor® 647 labeled ADP tracer from the antibody, resulting in a decrease in the TR-FRET signal.
- the amount of ADP formed by the kinase reaction is reduced, and the resulting intact antibody- tracer interaction results in a high TR-FRET signal.
- Test Compounds The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold serial dilutions are conducted from the starting concentration of the customer's choosing.
- Peptide/Kinase Mixtures All Peptide/Kinase Mixtures are diluted to a 2X working concentration in the appropriate Kinase Buffer.
- ATP Solution All ATP Solutions are diluted to a 4X working concentration in Kinase Buffer (50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgC12, 1 mM EGTA). ATP Km apparent is previously determined using a Z ' -LYTE® assay. Development Reagent Solution The Development Reagent is diluted in Development Buffer.
- Assay Protocol Bar-coded Corning, low volume NBS, black 384-well plate (Corning Cat. #4514) 1. 2.5 - 4X Test Compound or 100 nL 100X plus 2.4 kinase buffer. 2. 5 - 2X Peptide/Kinase Mixture. 3. 2.5 - 4X ATP Solution. 4. 30-second plate shake. 5. 60-minute Kinase Reaction incubation at room temperature. 6. 5 ⁇ - Development Reagent Solution. 7. 30-second plate shake. 8. 60-minute Development Reaction incubation at room temperature. 9. Read on fluorescence plate reader and analyze the data.
- ADP formation is determined by calculating the emission ratio from the assay well.
- the emission ratio is calculated by dividing the intensity of the tracer (acceptor) emission by the intensity of the Eu (donor) emission at 615 nm as shown in the equation below.
- the ADAPTA technology measures ADP formation (i.e. conversion of ATP to ADP) it can be used to measure any type of ATP hydrolysis, including intrinsic ATPase activity of kinases.
- the substrate is water, not a lipid or peptide.
- the SelectScreen® service screens CHUK in this way, so a substrate is not included in the kinase reaction.
- a reference for using intrinsic ATPase activity to screen for kinase inhibitors is provided below.
- Test Compounds The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold serial dilutions are conducted from the starting concentration of the customer's choosing.
- Substrate/Kinase Mixtures All Substrate/Kinase Mixtures are diluted to a 2X working concentration in the appropriate Kinase Buffer (see section Kinase Specific Assay Conditions for a complete description).
- ATP Solution All ATP Solutions are diluted to a 4X working concentration in water. ATP Km apparent is previously determined using a radiometric assay except when no substrate is available in which case an Adapta® assay is conducted.
- the Detection Mix is prepared in TR-FRET Dilution Buffer.
- the Detection mix consists of EDTA (30 mM), Eu-anti-ADP antibody (6 nM) and ADP tracer.
- the detection mix contains the EC60 concentration of tracer for 5-150 ⁇ ATP.
- Protein Lysates and Western Blotting [50 mmol/L Tris-HCl (pH 8.0), 150 mmol/L NaCl, 1% NP40, 0.5% Na-deoxycholate, 0.1% SDS, containing protease (P8340, Sigma, St. Louis, MO) and phosphatase (P5726, Sigma) inhibitor cocktails].
- the soluble protein concentration was determined by micro-bovine serum albumin assay (Pierce, Rockford, IL).
- Protein immunodetection was done by electrophoretic transfer of SDS-PAGE separated proteins to nitrocellulose, incubation with antibody, and chemiluminescent second step detection
- the antibodies included EGFR, phospho-EGFR (Y1068), phospho-p42/p44, phospho-Akt (473), phospho-Akt (308), total Akt, phosho-S6 (235/236), and total S6. All antibodies were obtained from Cell Signaling Technologies (Danvers, MA).
- Western Blotting Cell extracts were prepared by detergent lysis [25 mmol/L Tris-HCl (pH 7.6), 150 mmol/L NaCl, 1% Nonidet P-40, 10% glycerol, lmM EDTA, 1 mmol/L dithiothreitol (DTT), and protease and phosphatase inhibitors, rocked for 30 minutes at 4°C, and centrifuged at 14,000 rpm for 20 min at 4°C. Protein concentration was determined by BioRad Protein Assays and lysates were subsequently subjected to SDS gel electrophoresis.
- Proteins were transferred to poly vinylidene fluoride (PVDF) membranes and probed with primary antibodies recognizing EGFR, phospho-EGFR (Yl 068), phospho-p42/p44, phospho-Akt (473), phospho-Akt (308), total Akt and GAPDH (Abeam). After incubation with either anti-rabbit HRP or anti-mouse HRP linked secondary antibody (Jackson ImmunoResearch Laboratories, Inc.), proteins were detected using chemiluminescence (GE Healthcare).
- PVDF poly vinylidene fluoride
- NCI COMPARE Panel The human tumor cell lines of the cancer screening panel are grown in RPMI 1640 medium containing 5% fetal bovine serum and 2 mM L-glutamine.
- cells are inoculated into 96 well microtiter plates in 100 at plating densities ranging from 5,000 to 40,000 cells/well depending on the doubling time of individual cell lines. After cell inoculation, the microtiter plates are incubated at 37° C, 5 % C02, 95 % air and 100 % relative humidity for 24 h prior to addition of experimental drugs. After 24 h, two plates of each cell line are fixed in situ with TCA, to represent a measurement of the cell population for each cell line at the time of drug addition (Tz).
- TCA time of drug addition
- Experimental drugs are solubilized in dimethyl sulfoxide at 400-fold the desired final maximum test concentration and stored frozen prior to use.
- an aliquot of frozen concentrate is thawed and diluted to twice the desired final maximum test concentration with complete medium containing 50 ⁇ g/ml gentamicin. Additional four, 10-fold or 1 ⁇ 2 log serial dilutions are made to provide a total of five drug concentrations plus control. Aliquots of 100 ⁇ of these different drug dilutions are added to the appropriate microtiter wells already containing 100 ⁇ of medium, resulting in the required final drug concentrations.
- the plates are incubated for an additional 48 h at 37°C, 5 % C02, 95 % air, and 100 % relative humidity.
- the assay is terminated by the addition of cold TCA.
- Cells are fixed in situ by the gentle addition of 50 ⁇ of cold 50 % (w/v) TCA (final concentration, 10 % TCA) and incubated for 60 minutes at 4°C. The supernatant is discarded, and the plates are washed five times with tap water and air dried.
- Sulforhodamine B (SRB) solution (100 ⁇ ) at 0.4 % (w/v) in 1 % acetic acid is added to each well, and plates are incubated for 10 minutes at room temperature.
- the number reported for the One-dose assay is growth relative to the no-drug control, and relative to the time zero number of cells. This allows detection of both growth inhibition (values between 0 and 100) and lethality (values less than 0). For example, a value of 100 means no growth inhibition. A value of 40 would mean 60% growth inhibition. A value of 0 means no net growth over the course of the experiment. A value of -40 would mean 40% lethality. A value of - 100 means all cells are dead. Information from the One-dose mean graph is available for
- COMPARE analysis The heat map details green (%growth ⁇ 0, %growth >0% but less than 50%, %growth > 50%.
- mice Female 6-7 week old NCR nude mice (CrTac:NCr- ox «/ra from Taconic), 6-7 weeks old, were implanted subcutaneously with lxlO 6 to lx 10 7 cells in a 1 : 1 serum-free media/Matrigel® mixture into the region of the right axilla. Mice were randomized into treatment groups and treatments initiated when tumors reached 100 to 200mg. MTX-201 was administered daily for 10 days by oral gavage a s a clear yellow solution in 5% DMSO/95% PEG300, based upon individual animal body weight (0.2ml/20g). Subcutaneous tumor volume and body weights were measured two to three times a week.
- a complete response (CR) is defined as a tumor below the limits of palpation ( ⁇ 40 mg).
- Reaction conditions (i) iPrOH, 80°C, overnight; (ii) SiliaCatDpp-Pd 5 mol%, 10% K 2 C0 3 , EtOH, 125°C, 5-60 min., uW; (iii) (7F-H), pyridine, methanesulfonyl chloride, rt, 15 minutes
- the reaction mixture was placed under N 2 atmosphere, capped, and then heated at 125 °C for one hour in a Biotage Emrys Optimizer microwave.
- the reaction mixture was allowed to cool to room temperature and then filtered over a fritted funnel to collect SiliCat DPP-Pd.
- the filtered solid was rinsed with excess ethanol and the filtrate was concentrated under reduced pressure to afford the crude product.
- the reaction mixture was diluted with ethyl acetate, dichloromethane and methanol, washed with saturated sodium bicarbonate, water and brine, dried over magnesium sulfate, filtered and concentrated under vacuum.
- the crude material was purified by silica gel column chromatography eluting with a gradient of 2/98 to 25/75 methanol/ethyl acetate to afford 6-(5-aminopyridin-3-yl)-N-(3-chloro-4- methoxyphenyl)quinazolin-4-amine (7H) as an off white solid (524 mg, 33% yield).
- the reaction mixture was placed under N 2 atmosphere, capped, and then heated at 100 °C for 15 minutes in a Biotage Emrys Optimizer microwave.
- the reaction mixture was allowed to cool to room temperature and then filtered over a fritted funnel to collect SiliCat DPP-Pd.
- the filtered solid was rinsed with excess ethanol and the filtrate was concentrated under reduced pressure to afford the crude product.
- the reaction mixture was placed under N2 atmosphere, capped, and then heated at 100 °C for 15 minutes in a Biotage Emrys Optimizer microwave.
- the reaction mixture was allowed to cool to room temperature and then filtered over a fritted funnel to collect SiliCat DPP-Pd.
- the filtered solid was rinsed with excess ethanol and the filtrate was concentrated under reduced pressure to afford the crude product.
- Purification of the crude product by Biotage Isolera flash chromatography using a gradient of 4-100% ethyl acetate in heptane, followed by 0-10% methanol in
- the reaction mixture was allowed to cool to room temperature and was diluted with ethyl acetate, methanol and dichloromethane. The mixture was washed with water twice, then brine. The organic phase was dried over magnesium sulfate, filtered, and concentrated under reduce pressure. The residue was triturated under a mix of solvents, 50 mL ethyl acetate, 40 mL dichloromethane, 10 mL methanol, 0.25 mL ammonium hydroxide, for 1 hour and filtered. The solid was washed with ethyl acetate and dried in high vacuum to afford the title compound (5.92g, 57%).
- reaction mixture was stored at 0 °C overnight, diluted with 1 mL of dichloromethane and 3 drops of morpholine, (addition of morpholine resulted in a homogeneous solution) and applied directly to a 25 g column of silica gel for purification.
- the reaction mixture was sealed and heated at 100 °C for 20 minutes in a Biotage Emrys Optimizer microwave.
- the reaction mixture was cooled, the aqueous phase was removed, and the mixture was filtered through a glass frit.
- the solids were washed with methanol then hot methanol.
- the filtrate was concentrated under reduced pressure.
- the residue was diluted with methanol and ethyl acetate, concentrated under reduced pressure to give a solid.
- the solid was suspended in 20 mL of ethyl acetate. The addition of 2 mL of methanol resulted in a homogeneous solution.
- This example shows the synthesis procedure for additional quinoline based compounds of the present invention.
- reaction mixture was diluted with toluene and the volatiles were removed under vacuum and the crude material was purified by silica gel column chromatography eluting with a gradient of 3/7 to 7/3 ethyl acetate/heptane.
- 6-(5-amino-6-chloropyridin-3-yl)-4-((3-chloro-4-fluorophenyl)amino)quinoline-3-carbonitri A mixture consisting of 6-bromo-4-((3-chloro-4-fluorophenyl)amino)quinoline-3-carbonitrile - HC1 (1.2 g, 2.9 mmol), 2-methoxy-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-3- amine (1.1 g, 4.3 mmol) and 2.0M K2CO 3 (5.8 mL) in 15 mL of 1,4-dioxane was degassed
- the mother liquor was applied to a 120 g silica column eluted with a gradient of 65:35 ethyl acetate-heptane to 100% ethyl acetate to 15:85 methanol-ethyl acetate.
- the clean fractions containing product were combined and pale yellow solid was allowed to precipitate. It was filtered and dried to give 30 mg (2.5%) of the title compound.
- the filtered solid from above was dissolved in hot methanol-ethyl acetate (9: 1, 250 mL).
Abstract
Description
Claims
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201580075169.6A CN107531665B (en) | 2014-12-15 | 2015-12-15 | Small molecule inhibitors of EGFR and PI3K |
EP15870877.6A EP3233085B1 (en) | 2014-12-15 | 2015-12-15 | Quinazoline compounds as inhibitors of egfr and pi3k |
JP2017532165A JP6559785B2 (en) | 2014-12-15 | 2015-12-15 | Small molecule inhibitors of EGFR and PI3K |
KR1020177019457A KR102139496B1 (en) | 2014-12-15 | 2015-12-15 | Small molecule inhibitors of egfr and pi3k |
NZ732511A NZ732511A (en) | 2014-12-15 | 2015-12-15 | Small molecule inhibitors of egfr and pi3k |
US15/536,528 US10206924B2 (en) | 2014-12-15 | 2015-12-15 | Small molecule inhibitors of EGFR and PI3K |
AU2015362670A AU2015362670B2 (en) | 2014-12-15 | 2015-12-15 | Small molecule inhibitors of EGFR and PI3K |
CA2969974A CA2969974C (en) | 2014-12-15 | 2015-12-15 | Small molecule inhibitors of egfr and pi3k |
KR1020207021580A KR20200091954A (en) | 2014-12-15 | 2015-12-15 | Small molecule inhibitors of egfr and pi3k |
HK18105274.6A HK1248520A1 (en) | 2014-12-15 | 2018-04-23 | Small molecule inhibitors of egfr and pi3k |
US16/207,998 US10842791B2 (en) | 2014-12-15 | 2018-12-03 | Small molecule inhibitors of EGFR and PI3K |
AU2019202604A AU2019202604B2 (en) | 2014-12-15 | 2019-04-15 | Small molecule inhibitors of EGFR and PI3K |
US17/065,083 US11607414B2 (en) | 2014-12-15 | 2020-10-07 | Small molecule inhibitors of EGFR and PI3K |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462091969P | 2014-12-15 | 2014-12-15 | |
US62/091,969 | 2014-12-15 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/536,528 A-371-Of-International US10206924B2 (en) | 2014-12-15 | 2015-12-15 | Small molecule inhibitors of EGFR and PI3K |
US16/207,998 Division US10842791B2 (en) | 2014-12-15 | 2018-12-03 | Small molecule inhibitors of EGFR and PI3K |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2016100347A2 true WO2016100347A2 (en) | 2016-06-23 |
WO2016100347A3 WO2016100347A3 (en) | 2016-08-18 |
Family
ID=56127834
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2015/065827 WO2016100347A2 (en) | 2014-12-15 | 2015-12-15 | Small molecule inhibitors of egfr and pi3k |
Country Status (10)
Country | Link |
---|---|
US (3) | US10206924B2 (en) |
EP (1) | EP3233085B1 (en) |
JP (3) | JP6559785B2 (en) |
KR (2) | KR102139496B1 (en) |
CN (2) | CN107531665B (en) |
AU (2) | AU2015362670B2 (en) |
CA (2) | CA2969974C (en) |
HK (1) | HK1248520A1 (en) |
NZ (1) | NZ732511A (en) |
WO (1) | WO2016100347A2 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018085674A1 (en) * | 2016-11-03 | 2018-05-11 | The Regents Of The University Of Michigan | Small molecule dual inhibitors of egfr/pi3k and uses thereof |
CN108727342A (en) * | 2017-04-21 | 2018-11-02 | 沈阳药科大学 | 4- virtue ammonia -6- (3- sulfoamidos pyridine)-quinazoline derivative and its preparation method and application |
WO2019067543A1 (en) * | 2017-09-26 | 2019-04-04 | The Regents Of The University Of California | Compositions and methods for treating cancer |
WO2020190765A3 (en) * | 2019-03-15 | 2020-11-26 | The Regents Of The University Of California | Compositions and methods for treating cancer |
WO2023049312A1 (en) * | 2021-09-23 | 2023-03-30 | Erasca, Inc. | Egfr inhibitor polymorph forms |
WO2023069644A1 (en) * | 2021-10-20 | 2023-04-27 | Mekanistic Therapeutics Llc | Compounds useful in modulating egfr and pi3k |
US11673876B2 (en) | 2020-12-22 | 2023-06-13 | Mekanistic Therapeutics Llc | Substituted aminobenzyl heteroaryl compounds as EGFR and/or PI3K inhibitors |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11357857B2 (en) | 2014-06-20 | 2022-06-14 | Comera Life Sciences, Inc. | Excipient compounds for protein processing |
US10478498B2 (en) | 2014-06-20 | 2019-11-19 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
WO2015196091A1 (en) | 2014-06-20 | 2015-12-23 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
JP6559785B2 (en) * | 2014-12-15 | 2019-08-14 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | Small molecule inhibitors of EGFR and PI3K |
CN108929309B (en) * | 2018-06-14 | 2020-12-18 | 沈阳药科大学 | Preparation method and application of 4-arylamino-6-arylheterocyclyl-quinazoline anti-tumor compound |
CN109721554A (en) * | 2019-01-08 | 2019-05-07 | 贵州大学 | A kind of 4- amino-quinazoline compound and its preparation method and application |
CN110357852B (en) * | 2019-06-21 | 2022-06-10 | 中国药科大学 | Benzopyrimidine compounds, preparation method and application |
KR20220122993A (en) * | 2019-11-26 | 2022-09-05 | 코메라 라이프 사이언시스, 인코포레이티드 | Excipient compounds for biopolymer formulations |
CN114377024B (en) * | 2021-12-27 | 2023-10-24 | 南方医科大学南方医院 | Medicine for treating and/or preventing hyperlipidemia |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3989816A (en) | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
US4444762A (en) | 1980-04-04 | 1984-04-24 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacyclopentan-2-ones |
US5770581A (en) | 1990-12-20 | 1998-06-23 | Arch Development Corp. | Gene transcription and ionizing radiation: methods and compositions |
US20070249564A1 (en) | 1999-03-05 | 2007-10-25 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing prodrugs |
WO2008157191A2 (en) | 2007-06-14 | 2008-12-24 | Smithkline Beecham Corporation | Quinazoline derivatives as pi3 kinase inhibitors |
US20130165458A1 (en) | 2011-12-27 | 2013-06-27 | Development Center For Biotechnology | Quinazoline compounds as kinase inhibitors |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9603095D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
PT912559E (en) | 1996-07-13 | 2003-03-31 | Glaxo Group Ltd | HETEROCYCLIC COMPOUNDS FUSED AS PROTEIN INHIBITORS TYROSINE KINASE |
US6225318B1 (en) | 1996-10-17 | 2001-05-01 | Pfizer Inc | 4-aminoquinazolone derivatives |
EP0837063A1 (en) * | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
GB9800569D0 (en) * | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
JP3270834B2 (en) * | 1999-01-27 | 2002-04-02 | ファイザー・プロダクツ・インク | Heteroaromatic bicyclic derivatives useful as anticancer agents |
EP1396489A1 (en) * | 1999-01-27 | 2004-03-10 | Pfizer Products Inc. | Heteroaromatic bicyclic derivatives useful as anticancer agents |
AR035851A1 (en) * | 2000-03-28 | 2004-07-21 | Wyeth Corp | 3-CIANOQUINOLINS, 3-CIANO-1,6-NAFTIRIDINES AND 3-CIANO-1,7-NAFTIRIDINS AS INHIBITORS OF PROTEIN KINASES |
US6521618B2 (en) * | 2000-03-28 | 2003-02-18 | Wyeth | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors |
ES2201899B1 (en) | 2002-04-01 | 2005-06-01 | Almirall Prodesfarma, S.A. | DERIVATIVES OF AZAINDOLILPIPERIDINE AS ANTIHISTAMINIC AND ANTIALERGIC AGENTS. |
KR100735639B1 (en) | 2004-12-29 | 2007-07-04 | 한미약품 주식회사 | Quinazoline derivatives inhibiting the growth of cancer cell and preparation thereof |
PE20070207A1 (en) | 2005-07-22 | 2007-03-09 | Genentech Inc | COMBINED TREATMENT OF TUMORS THAT EXPRESS HER |
US8648087B2 (en) | 2005-11-15 | 2014-02-11 | Array Biopharma, Inc. | N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases |
EP1979327A1 (en) * | 2006-01-19 | 2008-10-15 | Janssen Pharmaceutica, N.V. | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
CN101003514A (en) * | 2006-01-20 | 2007-07-25 | 上海艾力斯医药科技有限公司 | Derivative of quinazoline, preparation method and usage |
DE102006012251A1 (en) * | 2006-03-15 | 2007-11-08 | Grünenthal GmbH | Substituted 4-aminoquinazoline derivatives and their use for the preparation of medicaments |
MX2008012928A (en) | 2006-04-04 | 2009-03-06 | Univ California | P13 kinase antagonists. |
US20080033000A1 (en) * | 2006-05-15 | 2008-02-07 | Senex Biotechnology, Inc. | Identification of CDKI pathway inhibitors |
MX2009000864A (en) * | 2006-07-28 | 2009-02-03 | Novartis Ag | 2,4-substituted quinazolines as lipid kinase inhibitors. |
EP2205076A4 (en) * | 2007-09-24 | 2010-12-29 | Tragara Pharmaceuticals Inc | Combination therapy for the treatment of cancer using cox-2 inhibitors and dual inhibitors of egfr ýerbb1¨and her-2 ýerbb2¨ |
EP2060565A1 (en) * | 2007-11-16 | 2009-05-20 | 4Sc Ag | Novel bifunctional compounds which inhibit protein kinases and histone deacetylases |
WO2009155527A2 (en) | 2008-06-19 | 2009-12-23 | Progenics Pharmaceuticals, Inc. | Phosphatidylinositol 3 kinase inhibitors |
US20100035919A1 (en) | 2008-08-05 | 2010-02-11 | Abbott Laboratories | Compounds useful as inhibitors of protein kinases |
GEP201706639B (en) * | 2009-08-17 | 2017-03-27 | Intellikine Llc | Heterocyclic compounds and uses thereof |
AR079814A1 (en) | 2009-12-31 | 2012-02-22 | Otsuka Pharma Co Ltd | HETEROCICLICAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USES |
DK2597955T3 (en) * | 2010-07-30 | 2016-03-14 | Onco Therapy Science Inc | QUINOLINE DERIVATIVES AND MILK INHIBITORS CONTAINING THESE |
DE102010049595A1 (en) | 2010-10-26 | 2012-04-26 | Merck Patent Gmbh | quinazoline derivatives |
US8664230B2 (en) | 2011-03-17 | 2014-03-04 | The Asan Foundation | Pyridopyrimidine derivatives and use thereof |
ITMI20110480A1 (en) | 2011-03-25 | 2012-09-26 | F I S Fabbrica Italiana Sint P A | PROCEDURE FOR THE PREPARATION OF LAPATINIB AND ITS SALTS |
AR086798A1 (en) | 2011-06-29 | 2014-01-22 | Otsuka Pharma Co Ltd | USEFUL QUINAZOLINIC DERIVATIVES TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
US9499530B2 (en) | 2011-08-01 | 2016-11-22 | Hangzhou Minsheng Institutes For Pharma Research | Quinazoline derivative, composition having the derivative, and use of the derivative in preparing medicament |
WO2013044169A1 (en) * | 2011-09-21 | 2013-03-28 | Nestec S.A. | Methods for determining combination therapy with il-2 for the treatment of cancer |
CN103304572A (en) * | 2012-03-09 | 2013-09-18 | 上海医药集团股份有限公司 | 3-cyanoquinoline compound as well as pharmaceutical composition and application thereof |
US20130331405A1 (en) * | 2012-06-12 | 2013-12-12 | The Regents Of The University Of California | PIK3CA Mutation Status and SASH1 Expression Predicts Synergy Between Lapatinib and an AKT Inhibitor in HER2 Positive Breast Cancer |
US20150259331A1 (en) * | 2014-03-17 | 2015-09-17 | Northeastern University | Protozoan parasite growth inhibitors |
JP6559785B2 (en) * | 2014-12-15 | 2019-08-14 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | Small molecule inhibitors of EGFR and PI3K |
-
2015
- 2015-12-15 JP JP2017532165A patent/JP6559785B2/en active Active
- 2015-12-15 CN CN201580075169.6A patent/CN107531665B/en active Active
- 2015-12-15 NZ NZ732511A patent/NZ732511A/en unknown
- 2015-12-15 AU AU2015362670A patent/AU2015362670B2/en active Active
- 2015-12-15 WO PCT/US2015/065827 patent/WO2016100347A2/en active Application Filing
- 2015-12-15 CA CA2969974A patent/CA2969974C/en active Active
- 2015-12-15 CN CN202110299508.6A patent/CN113354617A/en active Pending
- 2015-12-15 CA CA3081443A patent/CA3081443A1/en not_active Abandoned
- 2015-12-15 KR KR1020177019457A patent/KR102139496B1/en active IP Right Grant
- 2015-12-15 EP EP15870877.6A patent/EP3233085B1/en active Active
- 2015-12-15 KR KR1020207021580A patent/KR20200091954A/en active IP Right Grant
- 2015-12-15 US US15/536,528 patent/US10206924B2/en active Active
-
2018
- 2018-04-23 HK HK18105274.6A patent/HK1248520A1/en unknown
- 2018-12-03 US US16/207,998 patent/US10842791B2/en active Active
-
2019
- 2019-04-15 AU AU2019202604A patent/AU2019202604B2/en not_active Ceased
- 2019-07-17 JP JP2019131770A patent/JP2019206549A/en active Pending
-
2020
- 2020-10-07 US US17/065,083 patent/US11607414B2/en active Active
-
2021
- 2021-02-18 JP JP2021024620A patent/JP2021088580A/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3989816A (en) | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
US4444762A (en) | 1980-04-04 | 1984-04-24 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacyclopentan-2-ones |
US5770581A (en) | 1990-12-20 | 1998-06-23 | Arch Development Corp. | Gene transcription and ionizing radiation: methods and compositions |
US20070249564A1 (en) | 1999-03-05 | 2007-10-25 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing prodrugs |
WO2008157191A2 (en) | 2007-06-14 | 2008-12-24 | Smithkline Beecham Corporation | Quinazoline derivatives as pi3 kinase inhibitors |
US20130165458A1 (en) | 2011-12-27 | 2013-06-27 | Development Center For Biotechnology | Quinazoline compounds as kinase inhibitors |
Non-Patent Citations (23)
Title |
---|
"A Textbook of Drug Design and Development", 1991, GORDON & BREACH, article "Design and Applications of Prodrugs" |
"Bioreversible Carriers in Drug Design", 1987, ELSEVIER |
"Burger's Medicinal Chemistry and Drug Discovery", vol. 1, 1995, MACK PUBLISHING CO., pages: 172 - 178,949-982 |
"Pro-Drugs as Novel Delivery Systems", 1975, AM. CHEM. SOC. |
"Prodrugs: Topical and Ocular Drug Delivery", 1998, MARCEL DEKKER |
ATREYA CESANGALE ZXU N ET AL., CANCER MED, vol. 2, 2013, pages 496 - 506 |
BETHUNE G ET AL., J THORAC DIS, vol. 2, 2010, pages 48 - 51 |
BUCK E ET AL., MOL CANCER THER, vol. 5, 2006, pages 2676 - 2684 |
BUNDGARD: "Methods in Enzymology", vol. 42, 1985, ACADEMIC PRESS, pages: 309 - 9,21-24 |
EICHHORN PJ ET AL., CANCER RES, vol. 68, 2008, pages 9221 - 9230 |
FAN QW ET AL., CANCER RES, vol. 67, 2007, pages 7960 - 7965 |
GADGEEL SM ET AL., CLIN LUNG CANCER, vol. 14, 2013, pages 322 - 332 |
GOODMANGILMAN ET AL.: "Pharmaceutical Basis of Therapeutics", 2002 |
HAMADA K ET AL., GENES DEV, vol. 19, no. 17, 2005, pages 2054 - 65 |
HEIMBERGER AB ET AL., J TRANSL MED, vol. 3, 2005, pages 38 |
JIN G ET AL., LUNG CANCER, vol. 69, 2010, pages 279 - 283 |
LUI VW ET AL., CANCER DISCOV, vol. 3, 2013, pages 761 - 769 |
RATUSHNY V ET AL., CELL SIGNAL, vol. 21, 2009, pages 1255 - 1268 |
SAWAI H ET AL., BMC GASTROENTEROL, vol. 8, 2008, pages 56 |
See also references of EP3233085A4 |
SILVERMAN: "The Organic Chemistry of Drug Design and Drug Action", 1992, ACADEMIC PRESS, pages: 352 - 401 |
SPANO JP ET AL., ANN ONCOL, vol. 16, 2005, pages 189 - 194 |
UTE F. ROHRIG, JMC, vol. 55, no. 11, 2012, pages 5270 - 5290 |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018085674A1 (en) * | 2016-11-03 | 2018-05-11 | The Regents Of The University Of Michigan | Small molecule dual inhibitors of egfr/pi3k and uses thereof |
CN110022878A (en) * | 2016-11-03 | 2019-07-16 | 密执安大学评议会 | Small molecular double inhibitor of EGFR/PI3K and application thereof |
EP3534905A4 (en) * | 2016-11-03 | 2020-11-04 | The Regents of The University of Michigan | Small molecule dual inhibitors of egfr/pi3k and uses thereof |
CN108727342A (en) * | 2017-04-21 | 2018-11-02 | 沈阳药科大学 | 4- virtue ammonia -6- (3- sulfoamidos pyridine)-quinazoline derivative and its preparation method and application |
WO2019067543A1 (en) * | 2017-09-26 | 2019-04-04 | The Regents Of The University Of California | Compositions and methods for treating cancer |
WO2020190765A3 (en) * | 2019-03-15 | 2020-11-26 | The Regents Of The University Of California | Compositions and methods for treating cancer |
US11377451B2 (en) | 2019-03-15 | 2022-07-05 | The Regents Of The University Of California | Compositions and methods for treating cancer |
US11673876B2 (en) | 2020-12-22 | 2023-06-13 | Mekanistic Therapeutics Llc | Substituted aminobenzyl heteroaryl compounds as EGFR and/or PI3K inhibitors |
WO2023049312A1 (en) * | 2021-09-23 | 2023-03-30 | Erasca, Inc. | Egfr inhibitor polymorph forms |
WO2023069644A1 (en) * | 2021-10-20 | 2023-04-27 | Mekanistic Therapeutics Llc | Compounds useful in modulating egfr and pi3k |
Also Published As
Publication number | Publication date |
---|---|
NZ732511A (en) | 2018-11-30 |
US10842791B2 (en) | 2020-11-24 |
US20210023085A1 (en) | 2021-01-28 |
CA2969974C (en) | 2020-08-04 |
CN107531665A (en) | 2018-01-02 |
JP2021088580A (en) | 2021-06-10 |
EP3233085A2 (en) | 2017-10-25 |
US10206924B2 (en) | 2019-02-19 |
AU2019202604A1 (en) | 2019-05-02 |
US20170360788A1 (en) | 2017-12-21 |
AU2015362670B2 (en) | 2019-01-24 |
AU2015362670A1 (en) | 2017-06-29 |
WO2016100347A3 (en) | 2016-08-18 |
AU2019202604B2 (en) | 2020-09-24 |
US11607414B2 (en) | 2023-03-21 |
CN113354617A (en) | 2021-09-07 |
EP3233085A4 (en) | 2018-06-13 |
CN107531665B (en) | 2021-03-30 |
HK1248520A1 (en) | 2018-10-19 |
KR20170095328A (en) | 2017-08-22 |
EP3233085B1 (en) | 2022-09-07 |
CA2969974A1 (en) | 2016-06-23 |
CA3081443A1 (en) | 2016-06-23 |
KR102139496B1 (en) | 2020-07-30 |
KR20200091954A (en) | 2020-07-31 |
US20190167686A1 (en) | 2019-06-06 |
JP6559785B2 (en) | 2019-08-14 |
JP2017537959A (en) | 2017-12-21 |
JP2019206549A (en) | 2019-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11607414B2 (en) | Small molecule inhibitors of EGFR and PI3K | |
AU2015247646B2 (en) | MDM2 inhibitors and therapeutic methods using the same | |
EP3471712B1 (en) | Small molecule inhibitors of aldh and uses thereof | |
US20240083868A1 (en) | Substituted aminobenzyl heteroaryl compounds as egfr and/or pi3k inhibitors | |
WO2018081719A1 (en) | Small molecule inhibitors of nek2 and uses thereof | |
WO2023069644A1 (en) | Compounds useful in modulating egfr and pi3k | |
EP4288416A2 (en) | Small molecule inhibitors of grp78 and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15870877 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2969974 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2017532165 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15536528 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2015362670 Country of ref document: AU Date of ref document: 20151215 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20177019457 Country of ref document: KR Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2015870877 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15870877 Country of ref document: EP Kind code of ref document: A2 |